Equities

Kangmei Pharmaceutical Co Ltd

600518:SHH

Kangmei Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)2.31
  • Today's Change-0.09 / -3.75%
  • Shares traded544.76m
  • 1 Year change+22.87%
  • Beta1.0006
Data delayed at least 15 minutes, as of Nov 22 2024 07:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Kangmei Pharmaceutical Co., Ltd is a China-based company, principally engaged in the manufacture and sales of pharmaceutical products. The Company's principal products are Chinese medicines, including American ginseng, notoginseng powder, salvia powder, radix codonopsis pilosulae, maltiflower knotweed, angelica and lonicera flower, among others. The Company is also engaged in the trading of Chinese herbal medicines, medical equipment and healthcare products related businesses. It also engages in the provision of real estate leasing and distribution services, among others. The Company mainly conducts its businesses within domestic markets.

  • Revenue in CNY (TTM)5.21bn
  • Net income in CNY255.55m
  • Incorporated1997
  • Employees4.41k
  • Location
    Kangmei Pharmaceutical Co LtdTaike Road, Xiameilin, Futian DistrictSHENZHEN 518000ChinaCHN
  • Phone+86 75 533187777
  • Fax+86 75 586275777
  • Websitehttp://www.kangmei.com.cn/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Zhejiang Huahai Pharmaceutical Co., Ltd.9.35bn1.14bn27.11bn8.22k23.783.08--2.900.77720.77726.345.990.49221.023.511,137,186.006.015.678.378.0761.9760.5212.2111.610.79196.250.454133.550.519910.28-28.8850.517.21--
Hubei Jumpcan Pharmaceutical Co Ltd8.92bn2.78bn27.54bn5.23k9.861.96--3.093.033.039.7115.270.51353.084.601,706,101.0016.0416.2320.6820.8878.3682.6431.2324.423.55--0.102441.767.326.0230.0410.83-14.701.11
Gan & Lee Pharmaceuticals2.95bn580.86m28.03bn4.48k47.722.50--9.510.97730.97734.9718.650.25580.84588.94657,602.005.048.305.408.8372.9285.3919.7126.446.77--0.000513.6552.311.78177.37-18.301.50--
Xiamen Amoytop Biotech Co Ltd2.60bn740.69m30.02bn1.96k40.5313.26--11.571.821.826.385.571.080.89286.181,324,099.0030.7317.9635.9021.0292.7190.4828.5419.173.60--0.004426.9537.5536.1993.52103.2881.61--
Bluestar Adisseo Co14.95bn1.09bn30.25bn2.73k27.761.91--2.020.40640.40645.575.900.68875.188.015,466,479.005.035.286.076.9429.2030.317.308.761.167.830.110521.81-9.262.92-95.82-43.752.74-19.09
Kangmei Pharmaceutical Co Ltd5.21bn255.55m33.27bn4.41k129.594.73--6.380.01850.01850.37660.50790.36261.452.551,182,457.001.80-17.602.77-32.2420.63-72.784.95-101.190.8398--0.0346--16.60-22.17103.81-22.83-53.51--
Humanwell Healthcare Group Co Ltd25.56bn1.96bn38.85bn17.68k19.642.17--1.521.211.2115.8710.950.69023.802.741,445,825.007.136.2013.1212.7245.5942.8210.339.841.2112.090.317118.879.795.65-14.07--8.25--
Data as of Nov 22 2024. Currency figures normalised to Kangmei Pharmaceutical Co Ltd's reporting currency: Chinese Yuan Renminbi CNY

Institutional shareholders

4.13%Per cent of shares held by top holders
HolderShares% Held
Minmetals International Trust Co.,Ltd.as of 30 Jun 2023231.90m1.70%
Guangdong Finance Trust Co., Ltd.as of 30 Jun 2023181.82m1.34%
Chang'An International Trust Co., Ltd.as of 30 Jun 2023148.00m1.09%
Mellon Investments Corp.as of 07 Nov 2024233.93k0.00%
Amundi Asset Management SA (Investment Management)as of 05 Nov 202434.01k0.00%
UBS Asset Management Switzerland AGas of 31 Jul 202432.92k0.00%
F�rsta AP-fondenas of 30 Jun 202417.04k0.00%
UBS Asset Management (UK) Ltd.as of 31 Jul 20247.78k0.00%
DWS Investments (UK) Ltd.as of 07 Nov 20247.48k0.00%
Danske Bank A/S (Investment Management)as of 31 Oct 20247.35k0.00%
More ▼
Data from 30 Jun 2023 - 13 Nov 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.